# Nir Peled

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nir-peled/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,808 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 76 |
| i10-index | 228 |
| Last Known Institution | Hebrew University of Jerusalem |
| OpenAlex ID | https://openalex.org/A5033474030 |
| ORCID iD | https://orcid.org/0000-0003-3714-4377 |
| Works | 551 |

## Researcher papers

Showing 12 of 13.

- [Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-pd-l1-positive-non-small-cell-lung-cancer/)
- [Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-metastatic-non-small-cell-lung-cancer/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/updated-analysis-from-keynote-189-pembrolizumab-or-placebo-plus-pemetrexed-and/)
- [Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-fusion-positive-non-small-cell-lung-cancer/)
- [Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study](https://scholariq.org/papers/pembrolizumab-plus-pemetrexed-and-platinum-in-nonsquamous-non-small-cell-lung/)
- [Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC](https://scholariq.org/papers/liquid-biopsy-for-advanced-non-small-cell-lung-cancer-nsclc-a-statement-paper/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges](https://scholariq.org/papers/biomarkers-in-lung-cancer-screening-achievements-promises-and-challenges/)
- [Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations](https://scholariq.org/papers/characterization-of-298-patients-with-lung-cancer-harboring-met-exon-14-skipping/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Hebrew University of Jerusalem](https://scholariq.org/institutions/hebrew-university-of-jerusalem/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.